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Background: Rheumatic heart disease (RHD) remains a major health concern for Aboriginal Australians. A key
component of RHD control is prevention of recurrent acute rheumatic fever (ARF) using long-term secondary
prophylaxis with intramuscular benzathine penicillin (BPG). This is the most important and cost-effective step in
RHD control. However, there are significant challenges to effective implementation of secondary prophylaxis
programs. This project aimed to increase understanding and improve quality of RHD care through development
and implementation of a continuous quality improvement (CQI) strategy.
Methods: We used a CQI strategy to promote implementation of national best-practice ARF/RHD management
guidelines at primary health care level in Indigenous communities of the Northern Territory (NT), Australia,
2008–2010. Participatory action research methods were employed to identify system barriers to delivery of high quality
care. This entailed facilitated discussion with primary care staff aided by a system assessment tool (SAT). Participants
were encouraged to develop and implement strategies to overcome identified barriers, including better record-keeping,
triage systems and strategies for patient follow-up. To assess performance, clinical records were audited at baseline,
then annually for two years. Key performance indicators included proportion of people receiving adequate secondary
prophylaxis (≥80% of scheduled 4-weekly penicillin injections) and quality of documentation.
Results: Six health centres participated, servicing approximately 154 people with ARF/RHD. Improvements occurred in
indicators of service delivery including proportion of people receiving ≥40% of their scheduled BPG (increasing from
81/116 [70%] at baseline to 84/103 [82%] in year three, p = 0.04), proportion of people reviewed by a doctor within the
past two years (112/154 [73%] and 134/156 [86%], p = 0.003), and proportion of people who received influenza
vaccination (57/154 [37%] to 86/156 [55%], p = 0.001). However, the proportion receiving ≥80% of scheduled BPG did
not change. Documentation in medical files improved: ARF episode documentation increased from 31/55 (56%) to
50/62 (81%) (p = 0.004), and RHD risk category documentation from 87/154 (56%) to 103/145 (76%) (p < 0.001). Large
differences in performance were noted between health centres, reflected to some extent in SAT scores.
Conclusions: A CQI process using a systems approach and participatory action research methodology can significantly
improve delivery of ARF/RHD care.
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Acute rheumatic fever (ARF) and rheumatic heart disease
(RHD) remain important causes of illness and premature
death among young people in low-resource settings [1],
and among minority Indigenous populations in Australia,
New Zealand and elsewhere [2-6]. Aboriginal Australians
are almost 20 times more likely to die from ARF and RHD
than other Australians, with 40% of deaths occurring
in people aged ≤35 years [7]. RHD causes most of the
excess morbidity and mortality attributable to ARF [8].
While valve damage can occur after a single episode of
ARF, most RHD results from cumulative valvular insults
brought by recurrent episodes of ARF [9].
Primordial prevention of ARF targets social determinants,
particularly household crowding [3]. Primary prevention
is directed towards group A streptococcal infection, either
through antimicrobial treatment and/or vaccination.
As yet, no effective vaccine is available [10]. Secondary pre-
vention entails long-term, sometimes life-long, 3–4 weekly
intramuscular injections of benzathine penicillin G (BPG)
to prevent recurrent ARF in people with a history of
ARF or known RHD. Tertiary management addresses the
clinical consequences of established RHD [11-14].
Sustained reductions in ARF incidence could be achieved
by improvements in living conditions [9,15]. In the mean-
time, significant reductions in disease burden can be best
achieved through successful implementation of secondary
ARF prevention programs [16,17]. Primary prevention using
antibiotics for treatment of streptococcal pharyngitis has
proved to be of limited sustainability in remote Aboriginal
communities in the northern ‘Top End’ of Australia’s
Northern Territory (NT), largely because of the resource
commitment required. Symptomatic pharyngitis is also rare
despite the high rates of ARF [18-21]. Secondary prevention
of ARF with long-term 3–4 weekly BPG injections (Table 1)
has been proven to work and is cost-effective [17,22].
However, this strategy requires a well-functioning, properly-
resourced and highly-motivated primary health service. The
logistics of distance are often formidable. The focus
must be on children, adolescents and young adults; and
the injections are painful. Factors which intuitively would
be thought to be associated with adherence likelihood, such
as pain of needles and knowledge of ARF/RHD, are in fact
not necessarily the main determinants of adherence in ourTable 1 Rheumatic heart disease severity grading and indicat
Risk classification Clinical description
Low risk History of acute rheumatic fever with no evidence
heart disease OR trivial to mild valvular disease.
Medium risk Moderate valve lesion in the absence of symptom
normal left ventricular function OR mechanical pro
High risk Severe valvular disease OR moderate/severe valvu
symptoms OR tissue prosthetic valves and valve resetting [23]. Long-term daily oral penicillin is not accept-
ably effective [24], or feasible in remote settings. Rates of
penicillin allergy are fortunately low, with oral erythromycin
used in these few instances [13]. School-based delivery of
injections has proven to be very efficacious in New Zealand
[25], but is a limited option in our setting due to low school
attendance, recognised challenges in the implementation of
school-based health programs in remote communities, and
the requirement for ongoing prophylaxis for many people
after school-leaving age.
Effective control of RHD first requires active engagement
of primary health care staff backed up by a well-designed
and maintained ARF/RHD register. There is international
consensus that register-based programs are essential for
effective delivery of secondary prophylaxis at the com-
munity level and for coordinating follow-up [12,16,23].
In a setting of high medical and nursing staff turnover,
cultural disparities, vast distances and harsh climatic con-
ditions, sustainability of any chronic disease program is
the great challenge.
A critical measure of an effective secondary prevention
program is the rate of ARF recurrence. When a register-
based secondary prevention program was introduced in
the NT Top End in 1997 [26], around 45% of ARF cases
were recurrences [27]. By 2006, this proportion had fallen to
30% (Top End RHD Control Program – unpublished data).
In New Zealand, where ARF/RHD registers have been
operating for many years, documented recurrence rates
are less than 10% [28]. In a 2005 study of ARF prevention
in a large NT remote Aboriginal community, less than
half the people on the local register received 80% or
more of their scheduled BPG doses in the preceding
12 months, and more than half had missed follow-up
echocardiograms or specialist appointments [29]. There
is still much to be done before service delivery can be
regarded as acceptable across the region.
There has been strong uptake of systematic approaches
to continuous quality improvement (CQI) in the NT [30]
and in Indigenous primary health care services elsewhere
across Australia [31]. This has mainly been driven by the
Audit and Best Practice for Chronic Disease (ABCD) pro-
ject and the subsequent establishment of the National
Centre for Quality Improvement in Indigenous Primary
Health Care (One21seventy) [32]. CQI methods facilitateion for secondary prophylaxis [13]
Duration of secondary prophylaxis
of rheumatic Min 10 yrs after episode of ARF or age 21,
whichever is longer
s and with
sthetic valves.
Until age 35
lar lesion with
pairs.
Until age 40, or longer if ongoing exposure to GAS
remains high and risk also considered very high
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health performance data. The primary mechanism is direct
and active engagement of primary health staff. Such CQI
strategies are well-suited to Australian Indigenous primary
health settings [30] and have been shown to enhance health
centre systems, delivery of quality clinical care and various
intermediate outcomes [33]. An improved model of health
service delivery has already been shown to be an effective
strategy in reducing ARF rates; four decades ago, ARF
rates fell in parts of Baltimore, USA, between 1960–64
and 1968–70, in areas in which a ‘comprehensive-care
program’ was implemented, compared with the rest of
Baltimore [34].
Evidence-based guidelines for ARF/RHD diagnosis and
management [13,35] outline the basis for ARF/RHD
management nationally and internationally. These address
all aspects of ARF/RHD management from primordial
prevention to tertiary management of valvular lesions;
their recommendations on secondary prophylaxis inform
this study. Little is known about the extent of the gap
between best practice and actual practice across this
scope of ARF/RHD care. The aims of this project were
to enhance understanding of the gap between best
practice and actual practice in prevention and manage-
ment of RHD, and to improve ARF/RHD management
through development and implementation of a structured
systems approach in collaboration with remote NT
Indigenous health services. This involved integrating
the principles of the 2006 ARF/RHD National Guidelines
[35] into the ABCD program [36,37].
Methods
Study setting and processes
The primary health clinics were in regional and remote
Aboriginal communities in the Australia’s Northern
Territory (Top End and Central Australia). A project
management committee was established comprising the
lead project investigators, health service managers, clini-
cians, staff of the NT RHD Control Program, and staff of
RHD Australia [http://www.rhdaustralia.org.au/]. Participant
consent was not required for this quality improvement
audit. Ethics approval was given by the Health Research
Ethics Committees of the Northern Territory Department
of Health, Top End and Central Australia.
Development and implementation of CQI intervention
The first step was to specifically modify the pre-existing
ABCD processes and tools [32,37] for the ARF/RHD
project. The CQI intervention was delivered through
an action research design, whereby health centre staff,
RHD Control Program staff and other key stakeholders
were involved in the development of the tools. Experience
gained by participants and results of regular data feedback
were then used to continually revise and improve thetools. This action research process aimed to maximise
engagement and support of stakeholders at all levels,
from management to clinic primary care staff and support
personnel. The cyclical CQI process is summarised in
Figure 1. The CQI process has two essential components:
the RHD clinical audit tool for data collection from clinical
records and the ABCD Systems Assessment Tool for staff
to score their own performance.
RHD clinical audit tool
The project officer and local health centre staff used the
clinical audit tool (Additional file 1) and audit protocol to
assess the relevant clinical records of people with known
RHD or at least one episode of suspected or confirmed
ARF, who were known to have resided in the commu-
nity for at least six of the 12 preceding months. RHD
risk category (low, medium or high risk based on extent
of rheumatic valvular damage, see Table 1) was assigned
by the project officer on the basis of available clinical
information, unless already documented in the clinical
record. The key indicators of clinical performance were
determined by the evidence-based RHD guidelines [35]
and expert opinion of medical specialists experienced
in RHD and Aboriginal health. Audits were conducted
at baseline and annually for the next two years. Delivery
of ≥80% of scheduled BPG doses in the preceding
12 months is one recommended minimum benchmark,
[13] although it is well known that recurrent ARF can
occur after just one missed BPG injection.
ABCD systems assessment tool
The ABCD Systems Assessment Tool (SAT) (Table 2) was
used to assess the clinic systems required to support best
practice in prevention and management of ARF/ RHD. It
comprised an interactive process whereby a facilitator
engaged health centre staff (Aboriginal Health Workers,
nurses, doctors, administrative and other non-clinical staff)
in discussion and reflection on the strengths and weaknesses
of their health centre. They were encouraged to consider the
systems currently in place to support best practice. A scor-
ing tool (available via www.one21seventy.org.au), was then
completed as part of the process. Each health centre had
annual systems assessment with the SAT over the 3-year
project. The same facilitator conducted each SAT in order
to better standardise scoring between health centres and
over the project’s course. The process of determining SAT
scores was a key component of the action research meth-
odology and was not primarily intended to provide an ob-
jective measure of health centre performance, but rather
to stimulate reflection by the health centre team about po-
tential for system improvement. The determinants of rela-
tively good or relatively poor performance were identified
through a thematic analysis of data drawn from these
discussions and observations by the project officer.
Figure 1 Continuous quality improvement cycle.
Table 2 Components of the acute rheumatic fever and rheumatic heart disease services systems assessment tool
Domain Components
Delivery system design - team structure and function
- clinical leadership
- appointments and scheduling
- care planning
- systematic follow-up
- continuity of care
- client access and cultural competence
- infrastructure, supplies and equipment
Information systems and decision support - maintenance and use of electronic client lists
- evidence based guidelines
- specialist – generalist collaborations
Self-management support - assessment and documentation
- education and support
Links with the community, other health services
and other services and resources
- cooperation on governance and operations
- linking health service clients to other resources
- working out in the community
- cooperation on regional health planning and resource development
Organisational influence and integration - organisational commitment
- quality improvement strategies
- integration of systems in health centre
(formatted here as a list due to space constraints. See www.one21seventy.org.au for formatted version created for data collection).
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Data entry, analysis and reporting for the CQI process were
supported by the One21seventy web-based information
system [32]. We estimated that 6 NT health centres, cov-
ering approximately 150 people with ARF/RHD, would
provide an appropriately diverse range to ensure transfer-
ability and external validity of the findings. Analyses were
performed using Stata 10.0 (Stata Corporation, College
Station, TX, USA). Chi-squared tests for trend were used
to test differences in proportions.
Results
Characteristics of participating health centres
From January 2008 to December 2010, six remote
Aboriginal health centres were engaged in the study.
Table 3 shows their diversity in terms of population
size, geography, accessibility, staffing, record keeping
and governance arrangements.
The number of clinical records audited in each of the
three years was 154 in 2008, 145 in 2009 and 156 in 2010.
Factors accounting for year-to-year variation in numbers
were: 1. People moving into and out of communities par-
ticipating in the project; 2. New ARF/RHD diagnoses - 6
occurred in 4 communities; 3. Deaths in people with ARF/
RHD - 5 in 2 communities; 4. Inability to locate the clinical
file at the time of audit.
In the baseline audit, 136/154 (88%) of people were
aged ≥15 years, 12% 5–15 years and none <5 years; 95/154
(62%) were female, and 99% had Indigenous status re-
corded as Aboriginal (152 people) or Torres Strait Islander
(1 person). Over the three years <1% of clinical records
did not have Indigenous status recorded.
Variation between clinics
There was wide variation in achievement of key perform-
ance indicators between clinics. Proportions of people who
received ≥80% of scheduled BPG injections at baseline
ranged from <10% in one clinic to >70% at another with an
average across clinics of 25% [29/116] (see Figure 2). The
proportion of people for whom risk classification was docu-
mented at different health centres ranged from 25 to 100%
in year one of the study.
Risk classification
Overall, approximately 40% of people were in the medium
to high-risk RHD category; 70/154 (45%) in 2008, 52/145
(36%) in 2009, 61/156 (39%) in 2010. For 84-85% of people
it was possible to determine the category from documen-
tation in clinical record or through the auditor applying
an algorithm based on data in the clinical record. The pro-
portion of people with a diagnosis of RHD documented in
their clinical record that were identified as requiring sec-
ondary prophylaxis decreased over the study from 75% in
2008 to 67% in 2009 and 66% in 2010. This trend followedclinical review by a specialist paediatrician, internal
medicine physician or cardiologist. Among the subgroup
of people in the low-risk category, the proportion dropped
from 83% in 2008 to 63% in 2010.
Overall, there was frequent contact with the community
health centre; >80% of all people with RHD, including
those not requiring regular BPG, attended the clinic in
the 3 months prior to each audit. People in the high
and medium-risk categories were more likely to have
attended within the preceding month than those in low
or undetermined-risk categories (Table 4). The most
common reason cited for attending was ARF/RHD care.
The health practitioner who conducted the first assess-
ment was usually a nurse (41%-52% of people), followed
by an Aboriginal Health Worker (30-42%), then a General
Practitioner (12-14%).
Impact of the CQI process on documentation and health
care attendance
When compared with baseline, significantly more people
had documentation of recurrent ARF on their clinical
record summary page (p = 0.004) and had RHD risk cat-
egory (p < 0.001) and smoking status (p = 0.005) recorded
in their clinical record by the second or third years of the
study. There was no significant change in the proportion
of people with known RHD, and on the register, who had
the diagnosis of RHD documented in their clinical record
(Table 4).
The proportion of people who had clear documentation
of risk classification, and for whom the auditor did not
need to apply the algorithm, increased from 56% (87/154)
in 2008 to 71% (103/145) in 2009 and 76% (118/156) in
2010 (p < 0.001). This improvement was observed across
all health centres, except one where documentation of risk
was already 100% in the first year. Documentation of at-
tendance remained essentially unchanged over the three
years (Table 4). A record of recent attendance increased in
people in high and medium-risk categories, but decreased
in people at low or undetermined-risk. These changes
were not statistically significant.
Impact of the CQI process on delivery of care
In analysis of aggregated data across the 6 health centres,
we observed improvements for almost all indicators of
service delivery (Table 5). The trends were statistically
significant for the proportion of people with a record of
having received 40% or more of scheduled BPG injections
(p = 0.04), who had their BPG injections scheduled at four-
weekly intervals (p < 0.001), who had been reviewed by a
doctor within the past two years (p = 0.003), for people in
high and medium-risk categories who had been reviewed
by a doctor within the past six months (p = 0.004), and for
people who had received influenza immunisation within
the past 12 months (p = 0.001).
Table 3 Characteristics of participating health care centres
Health
centre
Approximate population Approximate
number of people
with ARF/RHD
Location of health centre Climate (tropical,
sub-tropical, desert)
Management: (Aboriginal
medical service [AMS],
Government)
Record keeping
(Electronic, paper, both)
Full-time doctor
(Yes, No)
A 1160 24 Remote community, 6 hour
drive on mostly sealed road
Desert AMS Both No (year 1)
Yes (years 2–3)
B 600 18 Remote community, 2 hour
drive on mostly unsealed road
Desert AMS Both Yes
C 1500 30 Remote island community,
2–3 hours flying time to major
service centre; weekly barge service
Tropical Government Paper No
D Main community – 115 21 Remote community, 2.5 hour drive
on sealed road to major service centre
Sub-tropical Government Both (transition from paper
to electronic during study)
No
Including outstations
serviced by clinic - 600
E 9022 42 Regional service centre Tropical AMS Electronic Yes
F 990 14 Remote community, 20 minute
drive to small town
Tropical Government Paper No
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Figure 2 Trends in key indicators. BPG Coverage = % patients receiving ≥80% of scheduled injections; Current script =% patients with a current
BPG prescription on file; Management Plans refers to % patients with a current management plan in the clinical record; Doctor review
(and Specialist review) refer to % patients with a record of having their health and RHD care reviewed by a doctor (specialist) within a specified
period in relation to RHD risk status; Echo =% patients with a record of having an echocardiogram within a specified period in relation to RHD
risk status; Dental review = % patients with a record of having a dental review within two years of the audit date. Solid lines each show data for a
specific health centre (as identified by the letters in the legend). The dashed line shows the aggregate data for the six health centres.
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Table 4 Documentation of rheumatic heart disease information in health centre clinical records of people with ARF/RHD1
Risk classification 2008 2009 2010 p value
Diagnosis recorded on Client’s clinical
record summary sheet
Recurrent or suspected recurrent
ARF episode
56% (31/55) 73% (44/60) 81% (50/62) 0.004
Rheumatic heart disease 84% (115/137) 86% (115/133) 90% (135/150) 0.12
Documentation of risk classification in
full clinical record
All 56% (87/154) 71% (103/145) 76% (118/156) <0.001
High/Med 36% (50/138) 43% (45/104) 46% (56/122) 0.11
Documentation of risk classification in
the clinical record summary sheet page?
All 29% (44/154) 34% (50/145) 56% (88/156) <0.001
High/Med 35% (24/69) 42% (22/52) 64% (39/61) 0.001
ARF/RHD management plan in notes All 46% (71/154) 57% (83/145) 53% (83/156) 0.22
High/Med 51% (35/69) 77% (40/52) 62% (38/61) 0.15
Low/Undetermined 42% (36/85) 46% (43/93) 47% (45/95) 0.50
Current prescription on file All 66% (77/116) 82% (81/99) 58% (60/103) 0.24
High/Med 72% (41/57) 82% (36/44) 64% (30/47) 0.41
Low/Undetermined 61% (36/59) 82% (45/55) 54% (30/56) 0.43
Smoking status recorded All 23% (36/154) 40% (58/145) 38% (60/156) 0.005
Attendance within the previous month All 68% (105/154) 63% (92/145) 65% (101/156) 0.53
High/Med 71% (49/69) 62% (32/52) 80% (49/61) 0.27
Low/Undetermined 66% (56/85) 65% (60/93) 55% (52/95) 0.56
Attendance within the previous three months All 84% (129/154) 90% (130/145) 86% (134/156) 0.59
High/Med 86% (59/69) 90% (47/52) 93% (57/61) 0.14
Low/Undetermined 82% (70/85) 89% (83/93) 81% (77/95) 0.77
1Except for the two indicators “Documentation of risk classification in clinical record” and “Documentation of risk classification in the clinical record summary
sheet” all risk classifications are based on documented risk classification where available or, if there was no clear documented risk classification, assessment by
auditor applying an algorithm to clinical data available in the record.
Bold text is used to highlight p-values of <0.05.
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the most important indicator. The proportion of people re-
ceiving ≥80% of scheduled BPG injections did not signifi-
cantly improve over the duration of the study. Among
people receiving <80% of scheduled injections, the propor-
tion who had a record of active recall plus at least one other
action taken to improve uptake, remained steady between
69% and 85% during the project. The actions taken to im-
prove BPG uptake changed over time: ‘prevention advice’,
‘family meetings’ and ‘development of action plans’ all
significantly decreased. Other actions in addition to the
initial recall, such as home visits, further written reminders,
phone text messages, significantly increased.
Assessment of the state of primary health care systems to
support best practice in RHD care
Overall SAT scores increased by one point between 2008
and 2010. Tests of statistical significance were not cal-
culated, given the somewhat subjective nature of these
scores, and because the purpose of these scores was to
engage and provide feedback to clinic staff in the par-
ticipatory CQI process. Overall scores for individual
health centres were all within 2 points of the mean score
for all health centres, with a range between 4 and 8 in2008, 5–8 in 2009 and 5–9 in 2010. Regarding individual
domains of the SAT, ‘organisational influence and integra-
tion’ showed the strongest indication of improvement, from
mean 6 points in 2008 to 8 points in 2010. Three system
component scores - ‘Delivery system design’, ‘Self-manage-
ment support’, and ‘Links with the community, other health
services and other services and resources’ - showed a one-
point increase during the study period. Thus the perceived
state of most system components appeared to improve over
the three years of the study. The changes in averaged scores
from all health centres was not marked for any particular
system component, but scores assigned by individual clinics
to specific items were seen to shift substantially between
baseline and follow-up.
Within the domain ‘Links with the community, other
health services and other services and resources’, the
system item on ‘cooperation on regional health plan-
ning and resource development’ showed a low baseline
score (4 in 2008), and the most marked improvement
(8 in 2010) of the SAT scores. The system item with
the highest average score across the six health centres
was ‘client access and cultural competence’; 8 in 2008,
9 in 2010, both scores 2 points above average for all
items for each of these years. The systems item which
Table 5 Documented delivery of clinical care
Risk classification1 2008 2009 2010 p value
Received 80% + of scheduled injections All 25% (29/116) 26% (25/97) 23% (24/103) 0.78
High/Med 30% (17/57) 32% (14/44) 28% (13/47) 0.83
Received 60% + of scheduled injections All 42% (49/116) 53% (51/97) 52% (54/103) 0.13
Received 40% + of scheduled injections All 70% (81/116) 76% (74/97) 82% (84/103) 0.04
Frequency of BPG injections scheduled
at four weekly
All people with documented requirement
for regular BPG injections
20% (23/116) 32% (31/97) 52% (54/103) <0.001
Actions to improve uptake for people
who received <80% of injections
Active recall 81% 70/86 94% 68/72 89% 70/79 0.15
Arrange BPG if out of community 59% 51/86 62% 45/72 63% 50/79 0.60
Prevention advice 64% 55/86 76% 38/72 39% 31/79 0.002
Family meeting 31% 27/86 17% 12/72 8% 6/79 <0.001
Action plan 28% 24/86 18% 13/72 5% 4/79 <0.001
Additional measures after first active recall
(home visits, delivery of written reminders,
phone text messages)
27% 23/86 24% 17/72 46% 36/79 0.01
Active recall plus at least one other
of the above strategies
for people who received <80% of injections 69% 59/86 85% 61/72 72% 57/79 0.56
Echocardiogram all within three years 55% (85/154) 60% (87/145) 62% (97/156) 0.21
high and medium risk within 12 months1 39% (23/69) 42% (22/52) 44% (27/61) 0.20
Documented review by doctor All within 2 years 73% (112/154) 83% (121/145) 86% (134/156) 0.003
within 6 months High/medium 46% (34/69) 67% (35/52) 74% (45/61) 0.004
within 12 months Low/undetermined 58% (49/85) 71% (66/93) 66% (63/95) 0.24
Documented dental review all within 2 years 11% (17/154) 20% (29/154) 16% (25/156) 0.26
High/medium within 12 months 10% (7/69) 21% (11/52) 18% (11/61) 0.21
Documented review by
cardiologist/physician
All within 2 years 51% (78/154) 49% (71/145) 56% (87/156) 0.36
High/medium within 12 months2 39% (27/69) 48% (25/52) 43% (26/61) 0.66
Influenza immunisation within 12 months All 37% (57/154) 54% (78/145) 55% (86/156) 0.001
High/medium 38% (26/69) 58% (30/52) 61% (37/61) 0.008
Pneumovax - at least three doses since birth All 0% (0/154) 0% (0/145) 13% (21/156) n/a
High/medium 0% (0/69) 0% (0/52) 20% (12/61) n/a
Record of provision of educational
materials about rheumatic fever
(DVD/video/written materials)
All 6% (9/154) 6% (9/145) 1% (2/156) 0.06
Prescribed warfarin High/medium 20% (14/69) 31% (16/52) 26% (16/61) 0.41
INR testing For those on Warfarin
(at least two INRs in past 6 months)
100% 100% 100% n/a
INR result Of those with test results, % within
recommended range
64% (9/14) 69% (11/16) 75% (12/16) 0.52
1recommendation is 3–6 monthly echocardiogram for high risk.
2recommendation is 6 monthly specialist review for high risk [13].
Bold text is used to highlight p-values of <0.05.
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years with no noticeable improvement was ‘infrastructure,
supplies and equipment’. The average scores for this item
were influenced by one health centre that had particularly
low scores (0–2) across all three years of the project.
The factors that were believed to be associated with
adequacy of delivery of ARF/RHD-related activities were
subjectively assessed by the project officer and other par-
ticipating investigators; these are listed in Table 6.Discussion
In a challenging clinical environment characterised by
sustained high rates of ARF/RHD, we have shown a
significant improvement in the delivery of care for
people with ARF/RHD in association with implementation
of a CQI process based on participatory action research
principles. Major findings include improvement in im-
portant indicators of clinical care, including delivery of
scheduled BPG injections, scheduling of injections at
Table 6 Summary of factors influencing performance of 6 remote NT health centres in delivering services to people
with ARF/RHD (Ordered in terms of amenability to change)
Determinants of relatively good performance Determinants of relatively poor performance
1. Clear allocation of responsibility for RHD program among health centre staff 1. Patient flows in health centre do not direct RHD clients to staff
responsible for RHD care
2. Good regional management – commitment to CQI, resourcing for CQI 2. Lack of clear allocation of responsibility for RHD care
3. Effective feedback and management action in response to feedback
from CQI process
3. Lack of effective outreach services
4. Good Aboriginal Health Practitioner involvement in health centre operations 4. Changes and inefficiencies in patient information systems
5. Good outreach arrangements – including drivers, Aboriginal
Health Practitioners
5. Lack of regular/stable staffing, including medical practitioner service
6. Public health-oriented chronic disease support from regional level
to health centres
6. Health Centre Management turnover, unstable management structure
7. Staff stability and continuity, including availability of experienced GP 7. Larger number of clients, complexities of urban environment
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of regular review by a medical specialist. While the gap
between actual care delivered and best practice leaves
much room for improvement, the successes achieved are
a positive development towards attaining better outcomes.
Significant improvements in clinical record-keeping relat-
ing to ARF/RHD were also achieved.
Yet the proportion of people receiving ≥80% of sched-
uled BPG did not improve, remaining around 25% across
all six health centres over the three years of the study.
This is consistent with data on the regional RHD register
for the period covered by this study (unpublished data).
Thus, although many people were receiving greater per-
centages of their BPG doses by the end of the study, it is
clear that achievement of best practice is a long way off.
The impact of the improvement we found (an increase
in people getting ≥40% of their scheduled BPG doses) on
population RHD burden is difficult to predict, as the
relationship between needles received and RHD is non-
linear, depending on Group A Streptococcal exposure
pressures and strain type in circulation, and host factors.
In recent years, there is evidence that overall in the
NT, adherence has improved in the lower ranges -
fewer people are receiving <50% of injections, more are
receiving 50-80%, but without substantial changes to
those receiving >80%. While this is not ideal, and is a
rationale for further planned interventions to achieve
better outcomes, it appears to have correlated with re-
ductions in recurrence rates [46].
A key output of the project has been the development
of a clinical audit tool consistent with the 2006 and
current National ARF/RHD Guidelines [13,35]. This
tool has proved suitable for measuring change in key
performance indicators within a CQI process in diverse
regional and remote Indigenous primary health care
services. It is available via the One21seventy website
[32]. The project provided substantial capacity-building
opportunities for both Aboriginal and non-Aboriginal staffof the health services engaged in the project. The action
research method implemented is an important means of
optimising key stakeholder engagement and support for
the project from management level to the health centre
frontline staff. The ABCD process used in this study has
successfully improved the care of people with diabetes mel-
litus and other chronic diseases in Australian Indigenous
primary health care settings [30].
An important but unexpected outcome of the study
was the observed reduction in numbers of people requiring
ongoing secondary prophylaxis as a consequence of appro-
priate cessation after specialist review. Adults >21 years of
age with low-risk disease who have not had an episode
of ARF for the last 10 years do not require ongoing BPG
(Table 1). Inappropriate inclusion of people on clinic lists
for ongoing BPG generates excessive workloads, potentially
detracting from the quality of secondary prophylaxis deliv-
ery systems, and exposing people to unnecessary treatment.
ARF/RHD under-diagnosis and under-treatment have been
flagged as being the major concerns in this environment
[13,38], but we have demonstrated that over-treatment is
also an important issue and can be reduced by appropriate
specialist intervention.
The percentage of charts containing a current penicillin
prescription initially rose, then fell again to below baseline
in the third year of the study. A transition from paper to
electronic prescribing during the study period may have
contributed to these changes. Best practice requires an
up-to-date script be available, and prescription-writing
provides an opportunity for medical review of the file and
of the secondary prophylaxis stop date; however, absence of
a script does not prevent administration of injections since
nurse and Aboriginal health practitioners are authorised to
administer BPG injections regardless [39]. The proportion
of clients documented to have been provided with educa-
tional resources was disappointingly low throughout the
study. Improving the provision of culturally-relevant educa-
tional information, and the impact this may have on needle
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interpreting the audit data in this report important
considerations include: 1) changes in the numbers of
people on clinic ARF/RHD lists; 2) changes in the pro-
portion of people identified as requiring regular BPG
injections; 3) changes in risk classifications over time.
However the changes in these numbers were <10% of the
total number of records audited and are unlikely to have
significantly influenced findings.
The general challenges of providing good health care in
remote Australian Indigenous communities are not unique,
but have similarities with those experienced in First Nations
and Native American communities in North America/
Canada, and Maori communities in New Zealand. Some
of the solutions are also similar: e.g. the importance of
community control of health service delivery [40,41],
whereas other solutions are not: e.g. mobile telephone-
based solutions [42,43]. Although phone-based reminders
are used where possible, including in this study, this can
be hampered by high turnover of telephone numbers in
our setting. The specific challenges of ARF/RHD con-
trol in Indigenous societies are also not unique to our
setting. ARF/RHD burden is disproportionally borne
by Indigenous populations globally [44]. The early suc-
cesses of New Zealand’s ARF/RHD register [28] helped
to provide impetus for the creation of the Australian
Northern Territory register; RHD registers as the basis for
RHD control programs also exist in India, Cuba, Egypt
[45] and elsewhere. We are unaware however of literature
from non-Australian settings dealing with CQI processes
at health service level to improve ARF/RHD control.
Limitations of the study include the lack of a compari-
son group and lack of multiple observations prior to im-
plementation of the CQI process. However, the study was
not intended to demonstrate a causal effect, but rather to
describe trends in guideline scheduled services in associ-
ation with the implementation of a CQI process in the
context of very limited knowledge on adherence to best
practice guidelines for RHD care. The clinical audits rely
on documentation of information in health centre records
on the understanding that, if information is not clearly
documented, it is also unavailable to health staff respon-
sible for delivering care. Clinical audit data are not neces-
sarily an accurate reflection of the actual care delivered;
nevertheless they provide accessible, measurable indica-
tors likely to be closely associated with quality of care. As-
sessment of adherence to guidelines relies upon accurate
RHD risk classification. The appropriate risk category in
each case was not always clear from the clinical record,
but all efforts were made to assign correct risk level, based
on clinical and echocardiographic information, when
documentation was unavailable. Calculation of ‘days at
risk’ (the interval between 28 days from the last penicillin
dose and receipt of the next injection) was not assessed asit was not included in RHD audits at the time this research
was conducted (2008–2010). Finally, younger people in the
initial years after an episode of ARF are most important to
target for improved adherence strategies; local data shows
highest recurrence rates in the first year after ARF diagnosis
[46]. We did not analyse the effect of the CQI intervention
according to age or time elapsed since ARF diagnosis; how-
ever, the study aimed to assess overall impacts on clinical
performance, and our ongoing research aims to determine
differential effects of interventions by age and duration
since ARF diagnosis.
The operation of health centres was reflected somewhat
in their SAT scores. The component assessing ‘organisa-
tional influence and integration’ improved over 3 years, and
appeared to be related to performance in BPG prophylaxis.
Although the SAT scores were inherently subjective, the
project officer monitored and assisted in the assignment of
test scores for consistency and results were chiefly used to
engage clinic staff through the process of self-assessment.
While the data presented in this report cannot be
regarded as being representative of all health centres in the
region, they help us to understand the wide differences in
quality of RHD care between health centres and possible
contributing factors. There is a clear need to identify and
address obstacles in the way of best practice. Of course,
solutions must also be tailored to the specific needs of
each clinic. A substantial cause for optimism is the high
degree of engagement shown by people with ARF/RHD,
with up to 90% attending the clinic within a three-month
period, usually for ARF/RHD care. Such high rates of
attendance provide important opportunities for staff to
improve the quality of care, particularly adherence with
secondary prophylaxis.
Conclusion
In the absence of effective group A streptococcal vaccines,
primordial prevention offers a key long-term answer for
ARF/RHD in Aboriginal Australians and Torres Strait
Islanders, especially those living in remote communities.
In the meantime, secondary prevention is the best
cost-effective option, but this has proven to be difficult
to deliver. Key factors include evidence-based guide-
lines, well-resourced ARF/RHD register programs and
sustainable systems for effective service delivery at the
primary care level. The systems-directed quality improve-
ment approach described here is an important step towards
enhancing the prevention and management of ARF/RHD
in people at highest risk. The CQI process provides a
mechanism for engagement of individual practitioners,
health centre teams and those responsible for management
and delivery of care at regional and national levels. It identi-
fies priority areas that need attention. To be most effective,
any CQI process must be supported at a system-wide level,
with good leadership and management. Our findings point
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scheduled BPG injections. Any missed injection is a major
concern. As such, further CQI research should now focus
on the most effective interventions, taking in account
diverse community conditions, and sustainability.
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